Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC). Its earlier-stage pipeline includes preclinical compounds that the Company is evaluating in multiple rare diseases of unmet medical need, including methicillin-resistant staph aureus and NTM. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is an oral, reversible inhibitor of dipeptidyl peptidase 1. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. It has completed a Phase I study of INS1009.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:INSM
- CUSIP: N/A
- Web: www.insmed.com
Capitalization:- Market Cap: $1.77 billion
- Outstanding Shares: 62,377,000
Average Prices:- 50 Day Moving Avg: $17.85
- 200 Day Moving Avg: $17.15
- 52 Week Range: $10.21 - $31.39
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -12.86
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.34 per share
- Price / Book: 21.21
Profitability:- EBIDTA: ($180,870,000.00)
- Return on Equity: -130.41%
- Return on Assets: -85.48%
Debt:- Debt-to-Equity Ratio: 0.66%
- Current Ratio: 3.67%
- Quick Ratio: 3.67%
Misc:- Average Volume: 1.37 million shs.
- Beta: 0.74
- Short Ratio: 5.54
Frequently Asked Questions for Insmed (NASDAQ:INSM)
What is Insmed's stock symbol?
Insmed trades on the NASDAQ under the ticker symbol "INSM."
How were Insmed's earnings last quarter?
Insmed, Inc. (NASDAQ:INSM) announced its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.72) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.63) by $0.09. View Insmed's Earnings History.
Where is Insmed's stock going? Where will Insmed's stock price be in 2017?
7 brokers have issued 1-year price objectives for Insmed's stock. Their predictions range from $17.00 to $54.00. On average, they anticipate Insmed's share price to reach $36.71 in the next twelve months. View Analyst Ratings for Insmed.
Who are some of Insmed's key competitors?
Some companies that are related to Insmed include BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Spark Therapeutics (ONCE), AveXis (AVXS), Sarepta Therapeutics (SRPT), GW Pharmaceuticals PLC (GWPH), Axovant Sciences Ltd (AXON), Prothena Corporation PLC (PRTA), China Biologic Products (CBPO), Loxo Oncology (LOXO), Halozyme Therapeutics (HALO), Ultragenyx Pharmaceutical (RARE), Array BioPharma (ARRY), NovoCure Limited (NVCR), Aerie Pharmaceuticals (AERI), MyoKardia (MYOK), Intercept Pharmaceuticals (ICPT) and Acceleron Pharma (XLRN).
Who are Insmed's key executives?
Insmed's management team includes the folowing people:
- William H. Lewis, President, Chief Executive Officer, Director
- Paolo Tombesi, Chief Financial Officer
- S. Nicole Schaeffer, Senior Vice President- Human Resource and Corporate Services
- Walter Perkins Ph.D., Chief Technology Officer
- Eugene Jeffrey Sullivan M.D., Chief Product Strategy Officer and Chief Scientific Officer
- Mark Quigley, Vice President- Quality Assurance
- Christine A. Pellizzari, General Counsel, Corporate Secretary
- Roger Adsett, Chief Commercial Officer
- Paul Streck, Chief Medical Officer
- Donald J. Hayden Jr., Non-Executive Chairman of the Board
Who owns Insmed stock?
Insmed's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (14.98%), Palo Alto Investors LLC (9.01%), Vanguard Group Inc. (6.17%), State Street Corp (2.77%), Janus Henderson Group PLC (2.64%) and Emerald Advisers Inc. PA (2.07%). Company insiders that own Insmed stock include Andrew T Drechsler, Christine A Pellizzari, Donald J Hayden Jr, Melvin Md Sharoky, Myrtle S Potter, Orlov S Nicole Schaeffer and William Lewis. View Institutional Ownership Trends for Insmed.
Who sold Insmed stock? Who is selling Insmed stock?
Insmed's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Goldman Sachs Group Inc., AXA, TD Asset Management Inc., Ameriprise Financial Inc., California State Teachers Retirement System, Cornerstone Capital Management Holdings LLC. and ProShare Advisors LLC. Company insiders that have sold Insmed stock in the last year include Andrew T Drechsler, Donald J Hayden Jr, Melvin Md Sharoky, Myrtle S Potter and Orlov S Nicole Schaeffer. View Insider Buying and Selling for Insmed.
Who bought Insmed stock? Who is buying Insmed stock?
Insmed's stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Emerald Advisers Inc. PA, State Street Corp, Emerald Mutual Fund Advisers Trust, Nexthera Capital LP, Chartwell Investment Partners LLC, Palo Alto Investors LLC and Vanguard Group Inc.. Company insiders that have bought Insmed stock in the last two years include Christine A Pellizzari and William Lewis. View Insider Buying and Selling for Insmed.
How do I buy Insmed stock?
Shares of Insmed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insmed's stock price today?
One share of Insmed stock can currently be purchased for approximately $28.42.
MarketBeat Community Rating for Insmed (NASDAQ INSM)MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Insmed (NASDAQ:INSM) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 6 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.86) |
| Consensus Price Target: | $36.71 (29.18% upside) |
Analysts' Ratings History for Insmed (NASDAQ:INSM)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/6/2017 | Cowen and Company | Reiterated Rating | Outperform | $54.00 | High |  |
| 9/6/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $27.00 -> $43.00 | High | |
| 9/6/2017 | Robert W. Baird | Reiterated Rating | Outperform -> Positive | $23.00 -> $32.00 | High | |
| 9/6/2017 | HC Wainwright | Reiterated Rating | Buy | $35.00 | High | |
| 9/5/2017 | Leerink Swann | Boost Price Target | Outperform | $27.00 -> $36.00 | High | |
| 9/5/2017 | Evercore ISI | Boost Price Target | Outperform -> Outperform | $28.00 -> $40.00 | High | |
| 6/11/2017 | Citigroup Inc. | Reiterated Rating | Neutral | $14.00 -> $17.00 | High | |
| 8/21/2016 | Piper Jaffray Companies | Set Price Target | Buy | $24.00 | N/A | |
(Data available from 9/25/2015 forward)
Earnings History for Insmed (NASDAQ:INSM)Earnings History by Quarter for Insmed (NASDAQ INSM)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/3/2017 | Q2 2017 | ($0.63) | ($0.72) | | | View | Listen | |
| 5/3/2017 | Q1 2017 | ($0.60) | ($0.60) | $0.30 million | | View | Listen | |
| 2/23/2017 | Q316 | ($0.89) | ($1.10) | $0.30 million | | View | N/A | |
| 11/3/2016 | Q216 | ($0.59) | ($0.61) | $0.10 million | | View | N/A | |
| 8/4/2016 | Q2 | ($0.56) | ($0.59) | | | View | N/A | |
| 5/5/2016 | Q1 | ($0.56) | ($0.54) | | | View | N/A | |
| 2/25/2016 | Q415 | ($0.49) | ($0.51) | | | View | N/A | |
| 11/6/2015 | Q315 | ($0.48) | ($0.50) | | | View | N/A | |
| 8/6/2015 | Q2 | ($0.48) | ($0.47) | | | View | N/A | |
| 5/7/2015 | Q115 | ($0.49) | ($0.55) | | | View | N/A | |
| 2/27/2015 | Q414 | ($0.57) | ($0.36) | | | View | N/A | |
| 11/6/2014 | Q314 | ($0.51) | ($0.54) | | | View | N/A | |
| 8/6/2014 | Q214 | ($0.50) | ($0.59) | | | View | N/A | |
| 5/8/2014 | Q114 | ($0.39) | ($0.36) | | | View | N/A | |
| 3/6/2014 | Q413 | ($0.45) | ($0.41) | | | View | N/A | |
| 11/5/2013 | Q313 | ($0.41) | ($0.46) | | | View | Listen | |
| 8/6/2013 | Q2 2013 | ($0.32) | ($0.28) | $5.38 million | | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.46) | ($0.43) | | | View | Listen | |
| 11/7/2012 | Q312 | ($0.42) | ($0.38) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Insmed (NASDAQ:INSM)2017 EPS Consensus Estimate: ($2.40)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.58) | ($0.58) | ($0.58) |
| Q2 2017 | 1 | ($0.63) | ($0.63) | ($0.63) |
| Q3 2017 | 1 | ($0.59) | ($0.59) | ($0.59) |
| Q4 2017 | 1 | ($0.60) | ($0.60) | ($0.60) |
(Data provided by Zacks Investment Research)
Dividend History for Insmed (NASDAQ:INSM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Insmed (NASDAQ:INSM)Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 73.08%
Insider Trades by Quarter for Insmed (NASDAQ:INSM)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/7/2017 | Donald J Hayden Jr | Director | Sell | 45,000 | $29.67 | $1,335,150.00 | |
| 9/6/2017 | Melvin Md Sharoky | Director | Sell | 50,000 | $27.37 | $1,368,500.00 | |
| 5/31/2017 | Christine A Pellizzari | General Counsel | Buy | 10,000 | $15.14 | $151,400.00 | |
| 12/15/2016 | Christine A Pellizzari | General Counsel | Buy | 20,000 | $12.81 | $256,200.00 | |
| 12/14/2016 | Myrtle S Potter | Director | Sell | 6,466 | $12.79 | $82,700.14 | |
| 11/14/2016 | Andrew T Drechsler | CFO | Sell | 45,000 | $14.67 | $660,150.00 | |
| 11/9/2016 | Orlov S Nicole Schaeffer | SVP | Sell | 68,774 | $11.95 | $821,849.30 | |
| 2/1/2016 | William Lewis | CEO | Buy | 50,000 | $13.34 | $667,000.00 | |
| 9/2/2015 | Donald J. Hayden, Jr. | Director | Sell | 25,000 | $24.06 | $601,500.00 | |
| 5/12/2015 | Mark Quigley | VP | Sell | 18,750 | $22.07 | $413,812.50 | |
| 8/13/2014 | Melvin Md Sharoky | Director | Buy | 88,889 | $11.25 | $1,000,001.25 | |
| 11/1/2013 | William Lewis | CEO | Buy | 5,233 | $14.28 | $74,727.24 | |
| 7/22/2013 | Fmr Llc | Insider | Sell | 158,758 | $12.02 | $1,908,271.16 | |
| 7/18/2013 | Fmr Llc | Insider | Sell | 310,227 | $11.49 | $3,564,508.23 | |
| 7/15/2013 | Fmr Llc | Insider | Sell | 161,531 | $10.79 | $1,742,919.49 | |
| 7/9/2013 | Fmr Llc | Insider | Sell | 146,599 | $10.01 | $1,467,455.99 | |
| 7/3/2013 | Fmr Llc | Insider | Sell | 365,779 | $9.96 | $3,643,158.84 | |
| 7/1/2013 | William Lewis | CEO | Buy | 7,585 | $9.83 | $74,560.55 | |
| 6/24/2013 | Fmr Llc | Insider | Sell | 50,000 | $12.00 | $600,000.00 | |
| 6/20/2013 | Fmr Llc | Insider | Sell | 143,088 | $12.24 | $1,751,397.12 | |
| 6/12/2013 | Fmr Llc | Insider | Sell | 85,758 | $13.00 | $1,114,854.00 | |
| 6/6/2013 | Fmr Llc | Insider | Sell | 130,557 | $12.85 | $1,677,657.45 | |
| 4/1/2013 | William Lewis | CEO | Buy | 9,816 | $7.58 | $74,405.28 | |
| 1/9/2013 | William Lewis | CEO | Buy | 10,770 | $6.90 | $74,313.00 | |
| 12/3/2012 | William Lewis | CEO | Buy | 13,568 | $7.36 | $99,860.48 | |
(Data available from 1/1/2013 forward)
Headline Trends for Insmed (NASDAQ:INSM)
Latest Headlines for Insmed (NASDAQ:INSM)
| Source: |
|
| Date | Headline |
|---|
 | Commit To Purchase Insmed At $18, Earn 9.3% Annualized Using Options
www.nasdaq.com - September 22 at 1:48 PM |
 | Insmed Incorporated (INSM) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 20 at 2:30 AM |
 | Insmed to Present at Two September Investor Conferences - GlobeNewswire (press release)
globenewswire.com - September 19 at 7:58 PM |
 | Insmed to Present at Two September Investor Conferences
finance.yahoo.com - September 19 at 7:58 PM |
| Analysts Expect Insmed, Inc. (INSM) Will Announce Earnings of -$0.69 Per Share
www.americanbankingnews.com - September 19 at 10:46 AM |
| As Insmed Reaches New Highs, Is Matinas Following in Its Footsteps?
finance.yahoo.com - September 13 at 2:52 AM |
| Insmed Announces Closing of Public Offering
finance.yahoo.com - September 11 at 8:38 PM |
 | Insmed Prices Offering At $28.50/Share
www.rttnews.com - September 8 at 11:31 PM |
 | Insmed prices public offering of common stock
seekingalpha.com - September 7 at 8:10 PM |
| Insider Selling: Insmed, Inc. (INSM) Director Sells 45,000 Shares of Stock
www.americanbankingnews.com - September 7 at 7:22 PM |
| Insider Selling: Insmed, Inc. (INSM) Director Sells 50,000 Shares of Stock
www.americanbankingnews.com - September 7 at 7:20 PM |
| FY2018 EPS Estimates for Insmed, Inc. Cut by Analyst (INSM)
www.americanbankingnews.com - September 7 at 1:36 PM |
| Insmed's inhalable amikacin successful in late-stage study - Seeking Alpha
seekingalpha.com - September 7 at 12:54 AM |
 | Benzinga's Option Alert Recap From September 6 - Benzinga
www.benzinga.com - September 7 at 12:54 AM |
 | UPDATED: Insmed shares skyrocket 130% on positive late-stage results for rare lung disease therapy - MarketWatch
www.marketwatch.com - September 7 at 12:54 AM |
| Insmed Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 7 at 12:54 AM |
| Insmed Inc. (INSM) Vaulted To A New High On Phase 3 Study Results
www.rttnews.com - September 6 at 7:54 PM |
| Insmed (INSM) Top-line Data Indicates Phase 3 CONVERT Trial Met Primary Endpoint of Culture Conversion - Slideshow
seekingalpha.com - September 6 at 7:53 PM |
| Today's Research Reports on Stocks to Watch: Insmed Inc. and XOMA Corporation
finance.yahoo.com - September 6 at 7:53 PM |
| Insmed Incorporated (INSM) Catches Eye: Stock Soars 119.6%
finance.yahoo.com - September 6 at 7:53 PM |
| How Insmed Is Capitalizing on Its Huge Late-Stage Success
finance.yahoo.com - September 6 at 7:53 PM |
| Insmed's (INSM) Buy Rating Reaffirmed at Stifel Nicolaus
www.americanbankingnews.com - September 6 at 9:33 AM |
| Insmed, Inc. (INSM) Given Outperform Rating at Cowen and Company
www.americanbankingnews.com - September 6 at 9:33 AM |
| Insmed's (INSM) Positive Rating Reaffirmed at Robert W. Baird
www.americanbankingnews.com - September 6 at 9:17 AM |
| Insmed, Inc. (INSM) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - September 6 at 7:40 AM |
| Insmed Inc. (INSM) Has Surged To A New High On Phase 3 Study Results
www.nasdaq.com - September 6 at 6:25 AM |
 | Insmed shares skyrocket after lung drug meets key study's main goal
www.reuters.com - September 6 at 6:24 AM |
| UPDATED: Insmed shares skyrocket 130% on positive late-stage results for rare lung disease therapy
finance.yahoo.com - September 6 at 6:24 AM |
| Insmed More Than Doubles on Late-Stage Trial
finance.yahoo.com - September 6 at 6:24 AM |
| Why Did Insmed (INSM) Stock Skyrocket Today?
finance.yahoo.com - September 6 at 6:24 AM |
| Here's Why Insmed Incorporated Is Skyrocketing
finance.yahoo.com - September 6 at 6:24 AM |
| Insmed soars on positive lung drug study results
finance.yahoo.com - September 6 at 6:24 AM |
| Insmed Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 6 at 6:24 AM |
| Insmed, Inc. (INSM) Price Target Raised to $36.00 at Leerink Swann
www.americanbankingnews.com - September 5 at 10:28 PM |
| Insmed, Inc. (INSM) Price Target Raised to $40.00
www.americanbankingnews.com - September 5 at 7:48 PM |
 | Here's Why Insmed Incorporated Is Skyrocketing
www.fool.com - September 5 at 2:31 PM |
| Insmed Incorporated (INSM) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - August 26 at 2:34 AM |
| Evercore ISI Initiates Coverage on Insmed, Inc. (INSM)
www.americanbankingnews.com - August 16 at 6:26 PM |
| See what the IHS Markit Score report has to say about Insmed Inc.
finance.yahoo.com - August 9 at 8:13 PM |
| Are Options Traders Betting on a Big Move in Insmed (INSM) Stock?
finance.yahoo.com - August 9 at 8:13 PM |
| Insmed, Inc. (NASDAQ:INSM) Downgraded to Sell at BidaskClub
www.americanbankingnews.com - August 5 at 7:26 PM |
 | Form 8-K INSMED Inc For: Aug 03 - StreetInsider.com
www.streetinsider.com - August 5 at 6:44 PM |
| Edited Transcript of INSM earnings conference call or presentation 3-Aug-17 12:30pm GMT
finance.yahoo.com - August 4 at 1:03 AM |
| BRIEF-Insmed reports Q2 loss per share $0.72
www.reuters.com - August 3 at 8:03 PM |
| Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 3 at 8:03 PM |
| Insmed reports 2Q loss
finance.yahoo.com - August 3 at 8:03 PM |
| Insmed Incorporated (NASDAQ:INSM) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 1 at 8:01 AM |
| Insmed to Host Second Quarter 2017 Financial Results Conference Call on Thursday, August 3, 2017
finance.yahoo.com - July 27 at 11:00 PM |
| -$0.63 EPS Expected for Insmed, Inc. (NASDAQ:INSM) This Quarter
www.americanbankingnews.com - July 26 at 8:22 AM |
| Implied Volatility Surging For Insmed, Inc. (INSM) Stock Options - Nasdaq
www.nasdaq.com - July 18 at 2:23 AM |
Insmed (INSM) Chart for Monday, September, 25, 2017
